European grants
Secondary prEvention of CardiovascUlaR disease in the Elderly trial SECURE
Secondary prEvention of CardiovascUlaR disease in the Elderly trial SECURE
Project start date: 1. 5. 2015
Project completion date: 31 December 2021 (extended by 20 months on the basis of the third amendment to the grant agreement)
Project Budget: a total of EUR 5 998 786, of which EUR 219 884 for GIF, excluding co-financing from the GIF own resources
Project guarantor (workplace): II. internal clinic
Project Registration Number: 633765 - SECURE - H2020-PHC-2014-2015 / H2020-PHC-2014-two-stage
Project brief:
The project is supported by the EU Horizon 2020 program. The VFN participates in the project as one of the members of the international consortium. The project coordinator is the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) from Spain. In total, 11 organizations from eight European countries participate in the project.
The aim of the project is to prove the efficacy of a combined tablet (polypill) including drugs for the secondary prevention of acute myocardial infarction in patients after a coronary event over 65 years of age. The study aims to evaluate the potential benefit of polypill as part of a globally available and comprehensive treatment strategy aimed at preventing cardiovascular events secondary to conventional therapy (three components administered alone). Polypill has already been shown to be effective in initial studies with a combination of simvastatin, acetylsalicylic acid and an ACE inhibitor (FOCUS study - Fixed-Dose Combination Drug for Secondary Cardiovascular Prevention). Similarly, Polypill was more effective at controlling risk factors in the Kanyini GAP, IMPACT, and UMPIRE studies.
The General Teaching Hospital in Prague will cooperate with other hospitals in the Czech Republic. A total of 250 patients should be included in the study in the Czech Republic, some of them will be patients of the General Teaching Hospital, some of them will be from cooperating hospitals.
The aim of the study is to demonstrate that the simplification of treatment with atorvastatin - acetylsalicylic acid - ramipril in one tablet as a secondary prevention of cardiovascular events in the elderly is more effective compared to the mainstream therapy. The secondary result of the project is an assessment of the economic impact and comparison of regional differences.
https://www.vfn.cz/projekt-secure/
This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 633765.